Oncolytics Biotech Inc. (ONCY) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ONCY Revenue Growth
ONCY Revenue Analysis (2013–2024)
As of May 8, 2026, Oncolytics Biotech Inc. (ONCY) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, ONCY's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including CLDX (-78.6% YoY), NKTR (-43.9% YoY), and VVOS (+18.8% YoY). Compare ONCY vs CLDX →
ONCY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ONCYCurrent | $0 | - | - | - | |
 CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 VVOS | $15M | +18.8% | +5.7% | -74.3% | |
 AMGN | $36.7B | +9.1% | +7.6% | 29.1% |
ONCY Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-34,982,000 | - |
| 2023 | $0 | - | $-298,587 | - | $-25,036,175 | - |
| 2022 | $0 | - | $-301,109 | - | $-20,681,282 | - |
| 2021 | $0 | - | $-360,575 | - | $-20,925,470 | - |
| 2020 | $0 | - | $-332,652 | - | $-18,980,827 | - |
| 2019 | $0 | - | $-485,574 | - | $-20,693,357 | - |
| 2018 | $0 | - | $-95,375 | - | $-16,662,679 | - |
| 2017 | $0 | - | $-90,768 | - | $-15,605,454 | - |
| 2016 | $0 | - | $-162,233 | - | $-15,294,507 | - |
| 2015 | $0 | - | $-180,411 | - | $-13,917,701 | - |
See ONCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ONCY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ONCY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonONCY — Frequently Asked Questions
Quick answers to the most common questions about buying ONCY stock.
Is ONCY's revenue growth accelerating or slowing?
ONCY TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ONCY's long-term revenue growth rate?
Oncolytics Biotech Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ONCY's revenue distributed by segment?
ONCY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.